MERCK KGAA

The global infertility drugs market, valued at US$ 3.9 Billion in 2023, is projected to grow to US$ 6.0 Billion by 2032, with a CAGR of 4.90%. Growth is driven by rising infertility rates, public awareness, chronic health conditions, healthcare advancements, and generic drug demand. Key players include Abbott Laboratories, Bayer AG, and Ferring Pharmaceuticals.

Exscientia's Q1 2024 update highlights progress in AI-driven drug design, automation, and pipeline development, including advancements in CDK7, LSD1, and MALT1 inhibitors. The company expects to save $40M annually from 2025, extending cash runway into 2027, and emphasizes partnerships and operational efficiencies.

The global biotechnology market, valued at USD 1.54 Trillion in 2023, is projected to reach USD 5.68 Trillion by 2033, growing at a CAGR of 13.95%. Growth is driven by government support, personalized medicine, COVID-19 vaccine development, agricultural biotech applications, and advancements in gene editing and synthetic biology. North America leads the market, while Asia Pacific is expected to grow the fastest.

The Global Immuno-oncology Clinical Trials Market is projected to grow from USD 6.13 billion in 2023 to USD 12.87 billion by 2030, at a CAGR of 11.17%. The report analyzes market dynamics, competitive landscape, and profiles key vendors like AstraZeneca and BioNTech. It covers market segmentation by design, phase, indication, and regional prospects including North America, Asia-Pacific, and EMEA.

The oligonucleotide CDMO market is projected to grow from USD 2.51 billion in 2024 to USD 6.73 billion by 2029, with a CAGR of 21.8%. Key players include Thermo Fisher Scientific, Lonza, and Agilent Technologies. The market's expansion is driven by increasing demand for therapeutic, research, and diagnostic applications across pharma and biotech sectors.

Quris-AI and Merck KGaA extend collaboration after a successful preclinical study on Quris-AI's BioAI platform, which predicts drug toxicity more accurately than traditional methods. This partnership aims to advance drug development, reduce reliance on animal testing, and cut costs, with Merck KGaA having an option for a five-year exclusive license in a specific disease domain.

Integrin αvβ6 plays a crucial role in cell adhesion, migration, and signaling, with significant implications in cancer progression and epithelial-mesenchymal transition (EMT). Its up-regulation is linked to poor prognosis in various cancers, making it a potential target for cancer treatment. Research focuses on its biology, role in healthy humans, and therapeutic targeting strategies, including imaging and drug delivery approaches.

The UK aims to lead in clinical research post-Brexit, focusing on regulatory reform, NHS workforce and data infrastructure, patient engagement, and innovative treatments. Emphasizing AI, digital platforms, and global trials, it seeks to accelerate drug development, improve trial efficiency, and address global health challenges.

Sutro Biopharma, in collaboration with Merck, dosed the first patient in a Phase 1 study for a novel cytokine derivative therapeutic targeting cancer, triggering a $10 million payment to Sutro. This milestone highlights the synergy between Merck's immuno-oncology expertise and Sutro's biologics engineering capabilities.

Quris partners with Merck KGaA to evaluate its BioAI safety prediction platform, which uses miniaturized human tissues, nano-sensing, and machine learning for safer drug candidate predictions. The collaboration focuses on liver toxicity risks, with Merck KGaA having an option for a five-year exclusive license in a specific disease domain.